Michael Cardone leads Eutropics’ efforts to achieve corporate and scientific milestones. The company is using novel technology to extract unique insights from patient cancer cells that can be used to guide treatment. The PRIMAB® platform provides a breakthrough approach in cell signaling protein complex detection for guiding development and use of therapies for patients with cancer and immune disease. The novel predictive diagnostic tools have demonstrated utility for personalized medicine approaches. Michael Cardone’s experience includes 20 years of scientific and business management at early to mid-stage biotech companies. Prior to Eutropics, he was a scientific co-founder of publicly traded Merrimack Pharmaceuticals, a Cambridge, MA-based company. Prior to this, he worked at MIT developing tools for small molecule drug target identification and validation. He received a Ph.D. from UCSF and completed post-doctoral studies at the Burnham Institute in La Jolla, CA.
Prediction of Tumor Cell Response to Therapy
Eutropics' unique panel of antibodies, “PRIMABS®”, enable detection of tumor cell mitochondrial priming, a key determinant of cancer responsiveness to treatments. The presence (or absence) of the critical pro-survival : pro-apoptotic protein complexes, is used as a predictive biomarker for personalized medicine. Such reagents have hitherto not been available.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.